Redhill Biopharma: Q1 Earnings Insights


Shares of Redhill Biopharma RDHL were unchanged after the company reported Q1 results.

Quarterly Results

Earnings per share were flat 0.00% year over year to ($0.05), which beat the estimate of ($0.34).

Revenue of $20,575,000 up by 1848.39% year over year, which missed the estimate of $22,700,000.


Earnings guidance hasn't been issued by the company for now.

Redhill Biopharma hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: May 27, 2021

Time: 08:30 AM

ET Webcast URL:


52-week high: $11.52

Company's 52-week low was at $5.91

Price action over last quarter: down 6.25%

Company Description

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!